Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT05988463
What this trial is testing

Dose-Escalation Study of Artesunate Patients With IPF

Who this might be right for
Idiopathic Pulmonary Fibrosis
Joseph C. Wu 15
Not applicableNot Yet RecruitingNCT07722507
What this trial is testing

Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis

Who this might be right for
Pulmonary FibrosisIdiopathic Pulmonary FibrosisProgressive Pulmonary Fibrosis
Bristol-Myers Squibb 40
Not applicableStudy completedNCT05779007
What this trial is testing

Dose Reduction and Discontinuation With Anti-Fibrotic Medications

Who this might be right for
Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim 2,778
Testing effectiveness (Phase 2)Study completedNCT02477709
What this trial is testing

Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Who this might be right for
Idiopathic Pulmonary Fibrosis
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 6
Not applicableLooking for participantsNCT01776398
What this trial is testing

Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies

Who this might be right for
Chronic Obstructive Pulmonary Disease (COPD)SmokingSmoking Cessation+3 more
Weill Medical College of Cornell University 2,000
Early research (Phase 1)Study completedNCT01254409
What this trial is testing

A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Who this might be right for
Idiopathic Pulmonary Fibrosis
Hoffmann-La Roche 21
Not applicableWithdrawnNCT05676112
What this trial is testing

Safety of Nintedanib in Real World in China

Who this might be right for
Pulmonary Fibrosis
Boehringer Ingelheim
Testing effectiveness (Phase 2)Ended earlyNCT06097260
What this trial is testing

Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

Who this might be right for
Idiopathic Pulmonary Fibrosis
Pliant Therapeutics, Inc. 320
Testing effectiveness (Phase 2)Looking for participantsNCT06951217
What this trial is testing

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

Who this might be right for
Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc. 340
Not applicableStudy completedNCT02055222
What this trial is testing

Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease

Who this might be right for
Pulmonary FibrosisLung Disease
National Heart, Lung, and Blood Institute (NHLBI) 7
Not applicableStudy completedNCT01134822
What this trial is testing

Prospective Study of Fibrosis In the Lung Endpoints (PROFILE - Central England)

Who this might be right for
Idiopathic Pulmonary Fibrosis
University of Nottingham 330
Testing effectiveness (Phase 2)Ended earlyNCT06360094
What this trial is testing

Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis

Who this might be right for
Idiopathic Pulmonary FibrosisProgressive Pulmonary Fibrosis
Boehringer Ingelheim 85
Early research (Phase 1)Study completedNCT05427253
What this trial is testing

First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects

Who this might be right for
Safety IssuesToleranceIdiopathic Pulmonary Fibrosis+1 more
Vicore Pharma AB 80
Large-scale testing (Phase 3)Ended earlyNCT03733444
What this trial is testing

A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

Who this might be right for
Idiopathic Pulmonary Fibrosis
Lakefront Biotherapeutics NV 781
Not applicableStudy completedNCT05173571
What this trial is testing

Homecare Integral Support Program for IPF Patients

Who this might be right for
Idiopathic Pulmonary Fibrosis
Institut d'Investigació Biomèdica de Bellvitge 95
Not applicableLooking for participantsNCT07174102
What this trial is testing

Radiologic Features of Rheumatoid Arthritis Interstitial Lung Disease at Chest High Resolution Computed Tomography

Who this might be right for
Reumatoid ArthritisInterstitial Lung Disease Due to Systemic Disease (Disorder)Idiopathic Pulmonary Fibrosis (IPF)+1 more
Azienda Unita Sanitaria Locale di Piacenza 500
Testing effectiveness (Phase 2)Active Not RecruitingNCT06132256
What this trial is testing

MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Who this might be right for
Idiopathic Pulmonary Fibrosis
Syndax Pharmaceuticals 145
Not applicableStudy completedNCT05366387
What this trial is testing

Effect of Intrapulmonary Percussion Ventilation on Deposition of Inhaled Aerosols in Idiopathic Pulmonary Fibrosis

Who this might be right for
Idiopathic Pulmonary Fibrosis
University Hospital, Tours 9
Not applicableNot Yet RecruitingNCT07178392
What this trial is testing

Disease-syndrome Characteristics of IPF

Who this might be right for
Idiopathic Pulmonary Fibrosis (IPF)
Henan University of Traditional Chinese Medicine 2,864
Early research (Phase 1)Study completedNCT04720443
What this trial is testing

A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects

Who this might be right for
Idiopathic Pulmonary Fibrosis
The National Institutes of Pharmaceutical R&D Co. Ltd, China 56
Next Page